Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCELOTCMKTS:ENDVNYSE:KDMNNASDAQ:URGNNASDAQ:VNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCELAtreca$0.09$0.09$0.05▼$1.20$3.57M1.034.61 million shsN/AENDVEndonovo Therapeutics$0.00$0.00$0.00▼$0.00$240K-1.837.33 million shs150,200 shsKDMNKadmon$9.50$9.50$3.19▼$9.50$1.70BN/A5.11 million shs1,052 shsURGNUrogen Pharma$13.70+1.6%$9.34$3.42▼$18.15$621.99M0.41.07 million shs2.10 million shsVNDAVanda Pharmaceuticals$4.72-1.3%$4.40$3.81▼$6.37$281.71M0.66612,137 shs375,218 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCELAtreca0.00%0.00%0.00%0.00%0.00%ENDVEndonovo Therapeutics0.00%0.00%+100.00%0.00%-81.82%KDMNKadmon0.00%0.00%0.00%0.00%0.00%URGNUrogen Pharma0.00%-7.92%+233.91%+21.97%-19.61%VNDAVanda Pharmaceuticals0.00%+5.99%+8.88%+4.14%-15.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCELAtrecaN/AN/AN/AN/AN/AN/AN/AN/AENDVEndonovo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKDMNKadmonN/AN/AN/AN/AN/AN/AN/AN/AURGNUrogen Pharma4.545 of 5 stars4.52.00.04.52.52.50.0VNDAVanda Pharmaceuticals4.5664 of 5 stars3.82.00.04.22.03.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCELAtreca 0.00N/AN/AN/AENDVEndonovo Therapeutics 0.00N/AN/AN/AKDMNKadmon 0.00N/AN/AN/AURGNUrogen Pharma 3.00Buy$32.86139.83% UpsideVNDAVanda Pharmaceuticals 3.50Strong Buy$16.50249.58% UpsideCurrent Analyst Ratings BreakdownLatest VNDA, BCEL, ENDV, KDMN, and URGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.006/13/2025URGNUrogen PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$16.006/13/2025URGNUrogen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Buy$31.006/13/2025URGNUrogen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/13/2025URGNUrogen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$23.00 ➝ $47.006/13/2025URGNUrogen PharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $30.006/12/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/3/2025URGNUrogen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$36.00 ➝ $10.005/23/2025URGNUrogen PharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $15.005/22/2025URGNUrogen PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $3.005/14/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$13.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCELAtrecaN/AN/AN/AN/A$2.01 per shareN/AENDVEndonovo Therapeutics$10K24.13$0.02 per share0.01($0.08) per share0.00KDMNKadmonN/AN/AN/AN/AN/AN/AURGNUrogen Pharma$90.40M6.99N/AN/A($0.21) per share-65.24VNDAVanda Pharmaceuticals$198.77M1.40N/AN/A$9.24 per share0.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCELAtreca-$97.16M-$2.50N/AN/AN/AN/A-157.90%-71.39%N/AENDVEndonovo Therapeutics-$2.80MN/A0.00∞N/AN/AN/AN/AN/AKDMNKadmonN/AN/A0.00∞N/AN/AN/AN/AN/AURGNUrogen Pharma-$126.87M-$3.18N/AN/AN/A-150.68%-97,487.15%-49.57%8/12/2025 (Estimated)VNDAVanda Pharmaceuticals-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)Latest VNDA, BCEL, ENDV, KDMN, and URGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025URGNUrogen Pharma-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million5/7/2025Q1 2025VNDAVanda Pharmaceuticals-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCELAtrecaN/AN/AN/AN/AN/AENDVEndonovo TherapeuticsN/AN/AN/AN/AN/AKDMNKadmonN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCELAtrecaN/A1.581.58ENDVEndonovo TherapeuticsN/AN/AN/AKDMNKadmonN/AN/AN/AURGNUrogen Pharma4.775.655.47VNDAVanda PharmaceuticalsN/A3.933.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCELAtreca37.47%ENDVEndonovo TherapeuticsN/AKDMNKadmonN/AURGNUrogen Pharma91.29%VNDAVanda Pharmaceuticals88.14%Insider OwnershipCompanyInsider OwnershipBCELAtreca11.30%ENDVEndonovo Therapeutics5.61%KDMNKadmonN/AURGNUrogen Pharma5.10%VNDAVanda Pharmaceuticals8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCELAtreca13039.62 million35.15 millionOptionableENDVEndonovo Therapeutics11.21 billion1.14 billionNot OptionableKDMNKadmonN/A178.52 millionN/AOptionableURGNUrogen Pharma20046.11 million43.76 millionOptionableVNDAVanda Pharmaceuticals29058.93 million53.69 millionOptionableVNDA, BCEL, ENDV, KDMN, and URGN HeadlinesRecent News About These CompaniesVNDA - Vanda Pharmaceuticals Inc Chart - MorningstarJune 24, 2025 | morningstar.comMRisks of a blockade in the Strait of Hormuz 'remain absolutely minimalistic': Vanda InsightsJune 23, 2025 | youtube.comYInsider Selling: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells 7,000 Shares of StockJune 18, 2025 | insidertrades.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells $32,130.00 in StockJune 17, 2025 | marketbeat.comInsider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharmaceuticals Inc (VNDA)June 16, 2025 | gurufocus.comVanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to Hold at Wall Street ZenJune 14, 2025 | marketbeat.comBrokers Issue Forecasts for VNDA FY2026 EarningsJune 11, 2025 | marketbeat.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2SJune 10, 2025 | finanznachrichten.deVanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2SJune 10, 2025 | prnewswire.comJane Street Group LLC Decreases Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)June 8, 2025 | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Purchased by Two Sigma Investments LPJune 7, 2025 | marketbeat.comMillennium Management LLC Buys 269,183 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)June 1, 2025 | marketbeat.comVanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual MeetingMay 27, 2025 | prnewswire.comInsider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires 10,000 Shares of StockMay 22, 2025 | insidertrades.comInsider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Purchases 20,000 Shares of StockMay 20, 2025 | insidertrades.comInsider Buying: Mihael Polymeropoulos Acquires 20,000 Shares of Vanda Pharmaceuticals Inc (VNDA)May 20, 2025 | gurufocus.comVanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit ...May 16, 2025 | gurufocus.comVanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025May 16, 2025 | prnewswire.comVanda Pharmaceuticals (VNDA) Receives Overweight Rating from Cantor Fitzgerald | VNDA Stock NewsMay 14, 2025 | gurufocus.comVanda Pharmaceuticals (VNDA) Projected to Transform with Overweight Rating | VNDA Stock NewsMay 14, 2025 | gurufocus.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 9, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVNDA, BCEL, ENDV, KDMN, and URGN Company DescriptionsAtreca NASDAQ:BCELAtreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.Endonovo Therapeutics OTCMKTS:ENDV$0.0002 0.00 (0.00%) As of 03:52 PM EasternEndonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.Kadmon NYSE:KDMNKadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.Urogen Pharma NASDAQ:URGN$13.70 +0.21 (+1.56%) As of 04:00 PM EasternUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Vanda Pharmaceuticals NASDAQ:VNDA$4.72 -0.06 (-1.26%) As of 04:00 PM EasternVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
